Lichen China
LICN
2 hedge funds and large institutions have $683 invested in Lichen China in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.66% less ownership
Funds ownership: 0.66% → 0% (-0.66%)
96% less capital invested
Capital invested by funds: $19K → $683 (-$18.4K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$14.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $677 | -$14.8K | -4,106 | -94% |
|
|
2
Morgan Stanley
New York
| $6 | +$7 | +2 | New |
|
LICN Hedge Fund Activity: Q4 2025 in Review
2 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Lichen China (LICN) for Q4 2025, worth a combined $683 — down 96% from $19K a quarter earlier.
Fund positioning in LICN was balanced in Q4 2025: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $7. The largest seller was UBS Group, cutting an estimated $14.8K.
- 2 institutional investors held Lichen China (LICN) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $683 of Lichen China stock for Q4 2025, down 96% quarter-over-quarter.
- 1 fund opened new Lichen China positions in Q4 2025 and 1 closed out, a net change of 0 holders.
- The largest Lichen China buyer in Q4 2025 was Morgan Stanley, an estimated $7 added.
- The largest Lichen China seller in Q4 2025 was UBS Group, an estimated $14.8K sold.
Based on aggregated 13F filings for Q4 2025.